These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1878844)

  • 1. Use of intravenous immunoglobulin in various medical conditions. A Japanese experience.
    Abe T; Kawasugi K
    Cancer; 1991 Sep; 68(6 Suppl):1454-9. PubMed ID: 1878844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin: new clinical applications.
    Steele RW; Burks AW; Williams LW
    Ann Allergy; 1988 Feb; 60(2):89-94. PubMed ID: 2829663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the effect of immunoglobulin therapy in ITP.
    Kawasugi K; Matsuda J; Abe T
    Blut; 1989 Jul; 59(1):88-91. PubMed ID: 2752178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune thrombocytopenic purpura and intravenous immunoglobulin.
    Imbach P
    Cancer; 1991 Sep; 68(6 Suppl):1422-5. PubMed ID: 1878840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin therapy for idiopathic thrombocytopenic purpura and other immune-related disorders: review and update of our experiences.
    Imbach P
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S120-5. PubMed ID: 3135528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of intravenous immunoglobulins in pediatrics].
    Duse M; Plebani A; Crispino P; Ugazio AG
    Pediatr Med Chir; 1991; 13(2):117-25. PubMed ID: 1896376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
    Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation by intravenous immunoglobulin.
    Imbach P; Barandun S; Cottier H; Gugler E; Hassig A; Morell A; Wagner H; Heiniger H
    Am J Pediatr Hematol Oncol; 1990; 12(2):134-40. PubMed ID: 2198822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease associated with idiopathic thrombocytopenic purpura.
    Ishiguro N; Takahashi Y
    Eur J Pediatr; 1989 Jan; 148(4):379. PubMed ID: 2707285
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immunoglobulins as therapeutic agents.
    Stiehm ER; Ashida E; Kim KS; Winston DJ; Haas A; Gale RP
    Ann Intern Med; 1987 Sep; 107(3):367-82. PubMed ID: 3304051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
    Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of IVIG action in immune thrombocytopenic purpura.
    Hansen RJ; Balthasar JP
    Clin Lab; 2004; 50(3-4):133-40. PubMed ID: 15074465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.
    Takeuchi M; Ito S; Nakamura M; Kawakami K
    Paediatr Drugs; 2018 Dec; 20(6):585-591. PubMed ID: 30345488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
    Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome.
    Rigante D; Andreozzi L; Fastiggi M; Bracci B; Natale MF; Esposito S
    Int J Mol Sci; 2016 Feb; 17(3):278. PubMed ID: 26927060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S; Dong Y; Yin Y; Krucoff MW
    Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.